Moderna Stock Edges Higher Tuesday: What's Happening?
Key takeaways
- Moderna’s stock gains are driven by a breakthrough melanoma trial and analyst upgrades that boost its oncology outlook.
- Shares up 2.97%
- Price $143.01
- Price target $170
What happened
Moderna Inc. (NASDAQ: MRNA) shares rose 2.97% to $143.01 in pre‑market trading after analysts upgraded the stock, citing landmark Phase 3 oncology data from a melanoma trial in partnership with Merck & Co. (NYSE: MRK).
Why it matters
The trial, INTerpath‑001, demonstrated that the personalized mRNA vaccine intismeran autogene combined with the checkpoint inhibitor Keytruda met its primary endpoint of recurrence‑free survival and its secondary endpoint of distant‑metastasis‑free survival in high‑risk melanoma patients. This success strengthens…
Short-term and longer-term
Short-term. Short‑term traders should monitor MRNA’s price action around the $170 target set by BofA and watch for any further oncology data releases that could sustain the current upside.
Longer-term. Investors looking at a multi‑month horizon should note that Moderna’s oncology pipeline is now a more credible driver of future earnings, potentially diversifying its revenue beyond vaccines.